Relapses are observed in most hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear. The aim of this study was to assess the impact of different definitions on the rates of posttreatment relapse and therefore on the probability of retreatment in patients who have discontinued effective long-term NA therapy. In total, 130 HBeAg-negative chronic hepatitis B patients without cirrhosis and before NA treatment were included. All had on-therapy virological remission for 24 months and close follow-up for 12 months after stopping NA treatment or until retreatment, which started on stringent predefined criteria. Relapses rates based on several predetermined definitions of virological and perhaps biochemical criteria were assessed. The median duration of therapy was 60 months and the median duration of on-therapy virological remission was 43 months. During a median off-NAs follow-up of 15 months, no patient experienced liver decompensation or died. Cumulative relapse rates were 2%-49%, 4%-73%, 11%-82%, and 16%-90% at 3, 6, 12, and 24 months, respectively, whereas cumulative retreatment rates were 15%, 22%, and 40% at 6, 12, and 24 months, respectively, after discontinuation of NA therapy. No patient characteristic was independently associated with the probability of relapse based on at least two definitions or of retreatment. Conclusion: In HBeAg-negative chronic hepatitis B patients who discontinue NA therapy, the definition of relapse has a great impact on off-NAs relapse rates and potentially on the probability of retreatment. Regardless of definition, off-NAs relapses cannot be easily predicted by patient characteristics. A substantial proportion of such patients may not require retreatment if stringent criteria are adopted. (HEPATOLOGY 2018; 68:415-424).
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415 hepatology, Vol. 68, No. 2, 2018 VIRAL HEPATITIS N ucleos(t)ide analogues (NAs) are the most common therapeutic option used in patients with chronic hepatitis B (CHB).
(1,2) Among NAs, entecavir (ETV) or tenofovir disoproxil fumarate (TDF) have been used primarily in recent years due to their high potency and negligible (0%-1%) long-term risk of viral resistance.
(1-3) Long-term monotherapy with entecavir or tenofovir can achieve inhibition of hepatitis B virus (HBV) replication in almost all adherent CHB patients, whereas it normalizes alanine aminotransferase (ALT) activity, ameliorates liver necroinflammation and fibrosis, and reverses histological cirrhosis in the majority of patients. (4, 5) Because NAs cannot eradicate HBV from the liver and only rarely achieve hepatitis B surface antigen (HBsAg) loss, which is considered as the optimal treatment endpoint in all current guidelines, they should be given for very long periods, perhaps
SEE E D ITORIAL ON PAGE 397
indefinitely, in most CHB patients. (3, 6, 7) In particular, NAs can be discontinued in patients with HBeAgpositive CHB who achieve HBeAg loss, seroconversion to anti-HBe, and undetectable HBV DNA and receive 12 months of consolidation therapy after such a response. (3, 6, 7) According to current guidelines, NAs can be discontinued in patients with HBeAg-negative CHB only if they achieve HBsAg loss, which means that 95% of such patients will likely undergo indefinite therapy. (3, (6) (7) (8) Only in the Asia-Pacific region, where treatment is driven by cost restrictions, may NA therapy be discontinued after at least 2 years in HBeAgnegative CHB patients who had achieved undetectable serum HBV DNA on three occasions 6 months apart. (7) In addition, according to recent European guidelines, NA therapy may be discontinued in selected HBeAg-negative patients without cirrhosis who have achieved long-term (3 years) on-therapy virological suppression and will remain under close post-NA monitoring. (3) Although NAs have an excellent tolerance and a good safety profile, the need for long-term therapy may raise safety issues for some patients, especially the elderly, patients with comorbidities, and young patients of reproductive age who are undergoing family planning. (8, 9) In addition, there is an increasingly accumulating treatment cost, while many patients are keen to discontinue any long-term therapy. (8, 9) Thus, over the last few years, several groups have started assessing and reporting outcomes of CHB patients who discontinued NA treatment.
Virological relapses are observed in the majority of patients with HBeAg-negative CHB who discontinue NAs regardless of the duration of on-therapy virological remission. (9) However, virological relapses may not be always associated with biochemical relapses and/or may be temporary, leading to long-term virological and biochemical remission. (9) Data regarding predictors of sustained off-NAs virological remission have been conflicting, (9) and the optimal strategy to increase the rate of such sustained off-NAs remission remains unclear. (10) The aim of the present study was to assess the impact of different definitions of relapse on the rates of off-NAs remission and therefore on the probability of retreatment in patients with HBeAg-negative CHB who discontinued effective long-term NA therapy.
Patients and Methods
PATIENT POPULATION
This study included 130 adult patients with HBeAg-negative CHB who discontinued NA treatment within similar prospective studies conducted at the three participating centers (Academic Department of Gastroenterology at Laiko General Hospital of Athens, Athens, Greece; Second Academic Department of Internal Medicine at Hippokratio General Hospital of Athens, Greece; Department of Internal Medicine at National Taiwan University Hospital, Taipei, Taiwan). All patients had HBeAg-negative CHB without cirrhosis before the onset of NAs therapy and had discontinued NA treatment after at least 24 months of persistent on-therapy serum HBV DNA undetectability. All patients had been followed up prospectively for at least 12 months after NA discontinuation or until retreatment with NAs. No patient had coinfection with hepatitis C or D virus or human immunodeficiency virus, evidence of hepatocellular carcinoma or of any other malignancy, history of liver transplantation, or poor follow-up after NA discontinuation.
All patients gave written informed consent to discontinue NA treatment and agreed to remain under close follow-up. All patients participated in three different prospective studies, each of which was approved by the hospital's ethics committee.
ARTICLE INFORMATION:
FOLLOW-UP
According to standard clinical practice, all patients underwent a complete clinical and laboratory evaluation before the onset of NAs. The laboratory evaluation included ALT, HBV serological markers and HBV DNA determination, antibodies for hepatitis C or D virus or human immunodeficiency virus, and abdominal ultrasonography. HBV genotype was determined in 40 patients from Greece and all patients from Taiwan. The choice of the initial NA was made by the treating physicians influenced by local guidelines and regulations. During NA therapy, all patients were followed with ALT every 3 months, serum HBV DNA every 6 months and abdominal ultrasonography every 6 months. The upper limit of normal (ULN) for ALT was 40-41 IU/L for all participating centers. Serum HBV DNA was determined at each center by polymerase chain reaction assays with sensitivities of 45 IU/mL.
After NAs discontinuation, all patients were followed with physical examination, liver function tests including ALT and bilirubin levels, and serum HBV DNA levels. Depending on ALT and HBV DNA levels, follow-up was performed at least at month 1 and 3 (at month 2 in the Greek centers too) and then at least every 3 months until month 12 following NA discontinuation or until retreatment. Abdominal ultrasonography was also performed every 6 months.
DEFINITIONS
Before the onset of NAs, the diagnosis of HBeAgnegative CHB was based on positive HBsAg and negative HBeAg for at least 6 months, elevated ALT on at least two monthly determinations, and HBV DNA >20,000 IU/mL or HBV DNA >2000 IU/mL and histological lesions of at least moderate necroinflammatory activity and/or fibrosis. At the same period, absence of cirrhosis was defined as Ishak staging score of 4 or liver stiffness 10 kPa at transient elastography. On-therapy virological remission was defined by serum HBV DNA undetectability. Partial virological response was defined as a decrease in HBV DNA of >1 log 10 IU/mL but detectable HBV DNA after 12 months of NA therapy in compliant patients. Virological breakthrough was defined as a confirmed increase in HBV DNA level of >1 log 10 IU/mL compared with the nadir HBV DNA level on therapy.
The duration of NA therapy was considered as the interval between the date of onset of the initial NA therapy and the date of NA discontinuation, and the duration of on-therapy virological remission was considered as the interval between the date of the first detection of serum HBV DNA undetectability that persisted throughout therapy and the date of NA discontinuation. The duration of off-NAs follow-up was considered as the interval from the date of NA discontinuation until the last patients' visits for patients remaining without treatment or until retreatment for patients who were retreated.
Predetermined definitions of virological and combined virological and biochemical relapses after NA discontinuation, which were assessed in this study, were the following: HBV DNA >200 IU/mL, HBV DNA >2000 IU/mL, HBV DNA >20,000 IU/mL, HBV DNA >2000 IU/mL and ALT > ULN, HBV DNA >2000 IU/mL and ALT >23 ULN, HBV DNA >2000 IU/mL and ALT >23 ULN on two or more occasions, HBV DNA >2000 IU/mL and ALT >ULN on three or more occasions, HBV DNA >20,000 IU/mL and ALT > ULN, HBV DNA >20,000 IU/mL and ALT >23 ULN, HBV DNA >20,000 IU/mL and ALT >23 ULN, and bilirubin >2 mg/dL, HBV DNA >20,000 IU/mL and ALT >53 ULN, HBV DNA >20,000 IU/mL and ALT >103 ULN, HBV DNA >100,000 IU/mL and ALT >23 ULN, HBV DNA >100,000 IU/mL and ALT >33 ULN.
RETREATMENT CRITERIA
In the two Greek centers, prompt retreatment with ETV or TDF was mandatory in cases with ALT >103 ULN, ALT >53 ULN, and total bilirubin >2 mg/dL or ALT >33 ULN and HBV DNA >100,000 IU/mL. ETV or TDF was also initiated in cases with ALT > ULN and HBV DNA >2000 IU/ mL on three sequential occasions. In the Taiwanese center, prompt retreatment with ETV or TDF was mandatory in cases with ALT >23 ULN twice 3 months apart and HBV DNA >2000 IU/mL, total bilirubin >2 mg/dL, or prolongation of prothrombin time of 3 seconds.
STATISTICAL ANALYSIS
All data were analyzed using the statistical package SPSS (SPSS Inc., Chicago, IL, USA). Continuous variables are presented by their mean values 6 standard deviation or median values (interquartile range [IQR] ). Their comparison between two groups of patients was performed using a t test or nonparametric Mann-Whitney test. Categorical variables were summarized as frequencies and percentages. A chi-squared or Fisher's exact test was used to test for association between two categorical variables. Kaplan-Meier estimates of the cumulative probability of relapse were obtained and compared with a log-rank test. Cox proportional hazards regression models were used to estimate the effect of various variables on the hazard of relapse. Multivariable Cox proportional hazards models including all factors with significant or trends (P < 0.10) for significant associations in the univariable analyses were used to identify independent prognostic factors. Hazard ratios and 95% confidence intervals along with corresponding P values are presented; P < 0.05 was considered statistically significant.
Results
The main characteristics of the 130 patients are shown in Table 1 . Of the 130 patients, 76 (58.5%) were from the two Greek centers and 54 (41.5%) were from the Taiwanese center. Before the start of NA therapy, the median ALT level was 105 IU/L and the median HBV DNA level was 498,000 IU/mL. HBV genotype was B (n 5 43) and C (n 5 11) in the 54 patients from Taiwan and D in all 40 tested patients from the Greek centers. The initial NA therapy was modified in 42 (32%) patients due to virological partial response (n 5 8) or breakthrough (n 5 34). At NA cessation, ETV, TDF, and other NAs were taken by 41.5%, 48.5%, and 10% of patients, respectively (lamivudine, n 5 3; telbivudine, n 5 7; combination of two Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ETV, entecavir; IQR, interquartile range; NA, nucleos(t)ide analogue; SD, standard deviation; TDF, tenofovir disoproxil fumarate. *Includes 9 patients born in Albania and 1 patient born in Turkey.
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NAs, n 5 3). The median duration of therapy with NAs was 60 months, and the median duration of ontherapy virological remission was 43 months. In particular, the duration of on-therapy virological remission was 24-36 months in 58 (44.6%) patients and >36 months in 72 (55.4%) patients. All patients had normal ALT levels at NA discontinuation. The median off-NAs follow-up was 15 months (IQR, 13 months). No patient experienced jaundice, prothrombin time prolongation, or liver decompensation, nor did any of the patients die. One patient developed hepatocellular carcinoma diagnosed at 6 months after TDF discontinuation.
VIROLOGICAL RELAPSES
The cumulative rates of virological relapse based on the three predetermined serum HBV DNA cutoff levels of 200, 2000, and 20,000 IU/mL are shown in Figure 1 . The majority of patients experienced virological relapse defined as HBV DNA >200 IU/mL soon after NA discontinuation with 6-, 12-, and 24-month cumulative rates of 73%, 82%, and 90%, respectively. The majority of virological relapses also occurred within the first year after NA discontinuation when stricter criteria for the definition of relapse were used. In particular, the cumulative rates of virological relapse defined as HBV DNA >20,000 IU/mL were 48% at 12 months and increased to 63% at 24 months after NA discontinuation.
COMBINED VIROLOGICAL AND BIOCHEMICAL RELAPSES
The cumulative rates of combined virological and biochemical relapses based on the predetermined definitions are presented in Table 2 . Up to 55% of patients (48% at 12 months and 55% at 24 months) developed combined HBV DNA >2000 IU/mL and elevated ALT, while the cumulative rates of ALT elevations >23 ULN were around 40% combined with HBV DNA either >2000 IU/mL (38% at 12 months and 42% at 24 months) or >20,000 IU/mL (30% at 12 months and 38% at 24 months). Fewer patients developed ALT elevations >53 ULN (22% at 24 months) or >103 ULN (12% at 24 months) always combined with HBV DNA >20,000 IU/mL.
PREDICTORS OF RELAPSE
The significant or trends for significant univariable associations of any parameter of Table 1 on the probabilities of relapse according to different definitions are shown in Supporting Table S1 ; age, sex, body mass 23%  2%  5%  19%  18%  13%  10%  15%  12%  6  36%  29%  4%  9%  25%  23%  16%  11%  18%  14%  12  48%  38%  11%  15%  35%  30%  18%  11%  26%  20%  18  50%  42%  14%  22%  39%  34%  20%  12%  31%  25%  24  55%  42%  16%  25%  44%  38%  22%  12%  33%  27% Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B virus; ULN, upper limit of normal.
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index, ALT, AST, albumin, platelets, HBV DNA levels at start of NA therapy, and modification of initial NA therapy are not included because they had no association with relapse by any definition. Patient origin was also not included, because it was identical with patients' genotype (all patients from Greece had genotype D and all patients from Taiwan had genotype B or C). No difference was observed in the probabilities of relapse between patients with genotype B and C (data not shown).
In univariable Cox regression analyses, the probability of virological relapse defined as HBV DNA either >200 or >2000 IU/mL was significantly higher in patients with genotype D versus genotype B or C (P 5 0.004) those who were initially treated with NAs with a low barrier to resistance (lamivudine, adefovir dipivoxil, telbivudine) instead of NAs with a high barrier to resistance (ETV, TDF) (P 0.002) those who received TDF instead of ETV at treatment discontinuation (P 0.003) and those having longer total treatment duration (P 0.050). The probability of relapse defined as HBV DNA >2000 IU/mL and ALT >ULN had only a trend for association with patients receiving TDF instead of ETV at treatment discontinuation (P 5 0.085) and those being on longer virological remission (P 5 0.083), whereas the probability of relapse defined as HBV DNA >2000 IU/mL and ALT >23 ULN was significantly higher in patients initially treated with NAs with a low versus high barrier to resistance (P 5 0.042) and those receiving TDF instead of ETV at treatment discontinuation (P 5 0.031). The initial use of NAs with a low versus high barrier to resistance also significantly affected the probability of virological relapse defined as HBV DNA >20,000 IU/mL (P 5 0.019), whereas the probability of relapse defined as HBV DNA >20,000 IU/mL and ALT >23 ULN had only a trend for association with patients initially treated with NAs with a low versus high barrier to resistance (P 5 0.091) and those receiving TDF instead of ETV at treatment discontinuation (P 5 0.090). The probability of relapse defined as HBV DNA >20,000 IU/mL and ALT >53 ULN or >103 ULN was significantly higher in patients initially treated with NAs with a low versus high barrier to resistance (ETV, TDF) (P 0.011), receiving TDF instead of ETV at treatment discontinuation (P 0.024) and having longer total treatment duration (P 0.011). The probability of relapse defined as HBV DNA >20,000 IU/mL and ALT >ULN or as HBV DNA >100,000 IU/mL was not associated with any of the evaluated parameters.
In multivariable analyses, only the probability of relapse defined as HBV DNA >2000 IU/mL and ALT >ULN was significantly associated with use of TDF compared with ETV therapy at treatment discontinuation (P 5 0.029) and to have a trend for association with longer duration of on-therapy remission (P 5 0.056). All multivariable analyses results are presented in Table 3 .
RETREATMENT
Based on our predefined criteria, retreatment with ETV or TDF was initiated in 43 (33%) of the 130 patients. Retreatment was initiated because of ALT >103 ULN in 7 (28%), ALT >33 ULN and HBV DNA >100,000 IU/mL 11 (44%) and persistent ALT elevations with HBV DNA >2000 IU/mL in 7 (28%) of the 25 retreated patients in the Greek centers as well as because of ALT >23 ULN and HBV DNA >2000 IU/mL on two determinations in all 18 retreated patients in the Taiwanese center. The cumulative probability of retreatment was 15%, 22%, 30%, and 40% at 6, 12, 18, and 24 months after NA discontinuation (Fig. 2 ). All patients with at least 12 months follow-up after the start of retreatment achieved undetectable serum HBV DNA and normal ALT. In univariable Cox regression analyses, the probability of retreatment was found to be significantly associated with lower platelets at the start of NA therapy (P 5 0.045) and to have a trend for association with older age (P 5 0.058) and use of TDF as the last NA agent (P 5 0.079) ( Table 4) . In multivariable analysis, however, none of the above factors was significantly associated with the probability of retreatment. Similar findings were observed when the multivariable model also included the use of NAs with a low versus high barrier to resistance as initial therapy, which had a strong interaction with the use of ETV or TDF as the last NA therapy (TDF was the last NA agent in 88% of patients who were initially treated with a NA with a low barrier to resistance) ( Table 4 ). The associations of patient characteristics with the probability of retreatment did not substantially change when Greek and Taiwanese patients were assessed separately (data not shown).
In the 87 patients who have remained without retreatment, the median off-NAs follow-up was 18 months (IQR, 20 months; range, 12-59 months). At the last visit of these 87 patients, ALT levels were normal in 71 (81.6%) patients, elevated but <23 ULN in 14 (16.1%) patients, and 23 ULN in 2 (2.3%) patients, whereas serum HBV DNA was 2000 IU/ mL in 59 (67.8%) patients (49/71 patients with normal ALT and 10/14 patients with ULN < ALT <23 ULN), between 2000 and 20,000 IU/mL in 20 (23.0%) patients (17/71 patients with normal ALT and 3/14 patients with ULN < ALT <23 ULN), and >20,000 IU/mL in the remaining 8 (9.2%) patients (5/71 patients with normal ALT, 1/14 patients with ULN < ALT <23 ULN, and 2/2 patients with ALT 23 ULN).
Discussion
Several studies have already reported the outcomes of patients with HBeAg-negative CHB who discontinued NAs, but the systemic evaluation of the results has been quite challenging due to the great heterogeneity of the reports. (9, 10) Key factors of the heterogeneity among the published studies are reasonably considered to be the variable durations of treatment and on-therapy virological remission and the variable definitions of off-NAs response or relapse. (9, 10) Most of the relevant data so far come from Asia, where the guidelines recommend that NAs be discontinued rather early, primarily because of the economic burden of long-term therapy in limitedresource countries with high HBV prevalence, (9, 10) whereas there are quite limited data from Caucasian patients with HBeAg-negative CHB who discontinued NA therapy. (11, 12) Our study, which included 130 Caucasian and Asian patients with HBeAg-negative CHB who discontinued NA therapy after at least 24 months of on-therapy remission, confirms that the definition of relapse has a great impact on the rates of off-NAs remission and therefore potentially on the probability of retreatment in such patients. As expected, the vast majority of our Abbreviations: ADV, adefovir dipivoxil; ALT, alanine aminotransferase; ETV, entecavir; LAM, lamivudine; TBV, telbivudine; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal; VR, virological remission. Multivariable Cox regression analyses including only definitions of relapse with two or more factors having significant or trend for significant association (P < 0.10) in the univariable Cox regression analyses.
patients developed detectable HBV DNA soon after NA discontinuation, and the rates of HBV DNA >200 IU/mL were approximately 70%, 80%, and 90% at 6, 12, and 24 months of posttreatment follow-up. Similarly, if clinically significant relapse is considered to be the development of serum HBV DNA >2000 IU/mL alone, as suggested by scientific guidelines,
then approximately 55%, 70%, and 70% of patients would have been considered to have a relapse by 6, 12, and 24 months of posttreatment follow-up and would have been candidates for retreatment. The respective proportions of patients would be lower if HBV DNA >2000 IU/mL and abnormal ALT levels were required for a definition of posttreatment relapse, but approximately 35%, 50%, and 55% of patients would still have been considered to have a relapse by 6, 12, and 24 months after NA discontinuation. Our relapse rates are similar to or even higher than those reported in the literature so far. A recent systematic review reported pooled probabilities of virological remission at 12 months after NA discontinuation in HBeAgnegative CHB patients of 29% and 48% when the definition of virological remission was serum HBV DNA <200 and <2000 IU/mL, respectively.
Despite the high rates of relapse by the various definitions assessed in our study, only 22% or 40% of our patients were retreated after 12 or 24 months of post-NA follow-up due to the stringent predetermined criteria for retreatment. Additional patients may require to be retreated with prolongation of follow-up, but it should be noted that the majority of our patients remaining untreated had normal or slightly elevated ALT levels, usually in combination with low (<2000 Given that the median off-NAs follow-up of our untreated patients was 18 months (minimum, 12 months) and the risk of relapse seems to be decreasing with longer follow-up and particularly after the first year, (9, 13) most of these patients are expected to not require treatment, at least in the near future.
One of the limitations of our study is that the criteria for retreatment were not identical between the Taiwanese and the Greek centers. However, the probability of retreatment was not found to be affected by the patients' origin and therefore the criteria do not seem to affect retreatment if stringent criteria are adopted. In clinical practice, however, the criteria for retreatment of all centers were quite close; all but one of the 25 patients who were retreated in the two Greek centers fulfilled the retreatment criteria of the Taiwanese center at least at one time point, and many of them (if not all of them) might have fulfilled these criteria completely if they had received no therapy.
The identification of predictors of relapse after NA discontinuation is of great interest due to its potential impact on clinical practice. Unfortunately, none of the evaluated parameters was consistently found to be associated with the risk of relapse by most definitions in our study (Table 4) . Initial therapy with NAs with a low barrier to resistance, the use of TDF instead of ETV at treatment discontinuation, and longer total duration of NA therapy were factors more frequently found to be associated with higher risk of relapse according to some definitions in univariable analyses, whereas the use of TDF instead of ETV at treatment discontinuation and perhaps longer duration of ontherapy remission were found to be independently associated with the probability of relapse in multivariable analysis, but only for relapse defined as HBV DNA >2000 IU/mL and ALT > ULN. Whether there is a true different effect between TDF and ETV on the risk of relapse in this setting is unclear to date, but it has been reported that use of nucleotide versus nucleoside analogues results in increased levels of interferon k3 and eventually interferon-stimulated genes in vitro. (14) More importantly, no parameter was independently associated with the probability of retreatment in our study. These findings are in agreement with the existing literature, as no clear predictor of offNAs relapse or remission has been reliably identified to date. (9, 10) Although some potential predictors of offNAs relapse have been reported in a few published studies, (15, 16) none has been repeatedly confirmed in other and often larger studies. (9) Our findings justify the controversy of the reports on predictors of off-NAs relapse in CHB, as the predictability of the potential predictors is affected by the definition of relapse, which varied widely among the published studies. (9) It should be noted that in our study, it was not possible to evaluate the possible association between risk of relapse or retreatment and relatively short durations of NA therapy and most importantly of on-therapy virological remission (<24 months), as has been suggested previously, (9) because all our patients have remained in on-therapy virological remission for at least 24 months (median, 43 months). In addition, we did not assess the predictability of HBsAg levels as well as of new markers like the hepatitis B core related antigen and HBV RNA, which are considered to be promising. (3, 9) In conclusion, the definition of relapse strongly affects the off-NAs rates of relapse and therefore can have a great impact on the probability of retreatment in HBeAg-negative CHB patients who discontinue an effective long-term NA therapy. The majority of patients would be retreated within 12-24 months if clinically significant relapse and indication for retreatment are considered to be HBV DNA >2000 IU/mL even combined with elevated ALT levels, whereas retreatment would not be initiated in the majority of patients if more stringent criteria for retreatment initiation are adopted. Regardless of definition, off-NAs relapses cannot be easily predicted by the patients' main epidemiological and treatment characteristics; therefore, additional research is required in this field. Given that both Asian and European guidelines have now included the option of treatment discontinuation in HBeAg-CHB patients without cirrhosis who will remain under close monitoring, (3, 7) clinicians may start to withdraw oral antiviral agents in such patients who have remained in long-term (i.e., >2 years and preferentially >3 years) virological remission. Close posttreatment follow-up with at least ALT and HBV DNA determinations is mandatory, and strict and predefined criteria for retreatment are necessary for avoiding potential life-long retreatment in large proportions of these patients.
